Incorporating Continuous Mammographic Density Into the BOADICEA Breast Cancer Risk Prediction Model Cell-free DNA (cfDNA) and matched tumor sample from patients with BTC were analyzed using targeted ...

The 33 eligible patients had a median age of 71 years (range, 60-84) and a median CD22 expression of 92% (range, 21%-100%). Eight (24%) had previous chemotherapy or ...

Interestingly, while only 16% of oncology researchers reported using AI in biomarker detection and assessment at the time of ...

Oncology Unit proudly hosted a fifth visiting clinical oncology team from Canberra Hospital, Australia, from October 6 to 10, ...

In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of ...

School of Nursing seniors Jaidyn Morales-Devine (left) and Erica Di Corpo (right) spent their summers as Flynn Fellows ...

Highly specialized biotech CG Oncology (NASDAQ: CGON) was the subject of a new research report Wednesday, and its bullish ...

Harpreet Singh, MD, former director of the FDA's Division of Oncology 2 and chief medical officer of Precision for Medicine, ...

Ataraxis AI, a frontier laboratory developing artificial intelligence (AI)–powered prognostic tools for oncology, and MEDSIR ...

Explore the latest advancements in liquid biopsy for oncology, examining current trends and insights that could shape future ...

Race Oncology has achieved a breakthrough with its lead drug candidate RC220, identifying for the first time the primary ...